Silk Road Medical Inc.
A novel hybrid carotid artery stenting procedure
This article was originally published in Start Up
Executive Summary
Patients with carotid artery disease currently have two treatment options: traditional surgical repair or transfemoral stenting, but a new minimally invasive therapy that combines the benefits and minimizes the shortcomings of these two choices will soon be available. The ENROUTE procedure from Silk Road Medical Inc. consists of a neuroprotection system that reverses blood flow out of the brain to protect the brain from any debris that is liberated during the procedure, and a permanent stent that props open the narrowed carotid artery.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.